Biogen Inc. (BIIB)
Stock Price Chart
Key Info
| Market Cap | 40.78B |
| Revenue (ttm) | 14.26B |
| Net Income (ttm) | 5.08B |
| Shares Out | 153.88M |
| EPS (ttm) | 30.38 |
| PE Ratio | 8.72 |
| Forward PE | 9.52 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Oct 23, 2020 |
| Last Price | $265.00 |
| Previous Close | $266.80 |
| Change ($) | -1.80 |
| Change (%) | -0.67% |
| Day's Open | 267.23 |
| Day's Range | 262.16 - 267.23 |
| Day's Volume | 1,016,153 |
| 52-Week Range | 257.60 - 374.99 |
More Stats
| Market Cap | 40.78B |
| Enterprise Value | 45.03B |
| Earnings Date (est) | Feb 4, 2021 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 153.88M |
| Float | 153.62M |
| EPS (basic) | 30.26 |
| EPS (diluted) | 30.38 |
| FCF / Share | 37.71 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | 11.46% |
| FCF Yield | 14.51% |
| Payout Ratio | n/a |
| Shares Short | 2.83M |
| Short Ratio | 2.25 |
| Short % of Float | 1.84% |
| Beta | 0.52 |
| PE Ratio | 8.72 |
| Forward PE | 9.52 |
| P/FCF Ratio | 6.89 |
| PS Ratio | 2.86 |
| PB Ratio | 3.79 |
| Revenue | 14.26B |
| Operating Income | 6.66B |
| Net Income | 5.08B |
| Free Cash Flow | 5.92B |
| Net Cash | -4.25B |
| Net Cash / Share | -27.65 |
| Gross Margin | 87.09% |
| Operating Margin | 46.68% |
| Profit Margin | 35.60% |
| FCF Margin | 41.48% |
| ROA | 15.95% |
| ROE | 41.58% |
| ROIC | 36.90% |
Analyst Summary
Analyst Consensus: Overweight
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14,378 | 13,453 | 12,274 | 11,449 | 10,764 | 9,703 | 6,932 | 5,516 | 5,049 | 4,716 |
| Revenue Growth | 6.88% | 9.61% | 7.21% | 6.36% | 10.93% | 39.97% | 25.66% | 9.27% | 7.04% | - |
| Gross Profit | 12,423 | 11,637 | 10,644 | 9,970 | 9,523 | 8,532 | 6,075 | 4,971 | 4,582 | 4,316 |
| Operating Income | 7,043 | 5,889 | 5,346 | 5,152 | 4,922 | 3,917 | 2,491 | 1,809 | 1,725 | 1,249 |
| Net Income | 5,889 | 4,431 | 2,539 | 3,703 | 3,547 | 2,935 | 1,862 | 1,380 | 1,234 | 1,005 |
| Shares Outstanding | 187 | 205 | 213 | 218 | 231 | 236 | 237 | 238 | 242 | 252 |
| Earnings Per Share | 31.42 | 21.58 | 11.92 | 16.93 | 15.34 | 12.37 | 7.81 | 5.76 | 5.04 | 3.94 |
| EPS Growth | 45.6% | 81.04% | -29.59% | 10.37% | 24.01% | 58.39% | 35.59% | 14.29% | 27.92% | - |
| Operating Cash Flow | 7,079 | 6,188 | 4,551 | 4,587 | 3,919 | 2,942 | 2,345 | 1,880 | 1,728 | 1,625 |
| Capital Expenditures | -670 | -774 | -1,843 | -728 | -658 | -316 | -246 | -255 | -208 | -173 |
| Free Cash Flow | 6,409 | 5,414 | 2,708 | 3,860 | 3,261 | 2,626 | 2,099 | 1,625 | 1,520 | 1,452 |
| Cash & Equivalents | 4,476 | 3,538 | 3,689 | 4,895 | 3,429 | 1,845 | 1,223 | 1,706 | 1,691 | 1,208 |
| Total Debt | 6,368 | 5,937 | 5,938 | 6,517 | 6,526 | 583 | 596 | 1,141 | 1,064 | 1,204 |
| Net Cash / Debt | -1,892 | -2,399 | -2,249 | -1,622 | -3,098 | 1,262 | 627 | 565 | 627 | 4.21 |
| Assets | 27,234 | 25,289 | 23,653 | 22,877 | 19,505 | 14,315 | 11,863 | 10,130 | 9,050 | 8,092 |
| Liabilities | 13,895 | 12,257 | 11,055 | 10,748 | 10,130 | 3,501 | 3,242 | 3,166 | 2,623 | 2,643 |
| Book Value | 13,343 | 13,040 | 12,613 | 12,140 | 9,373 | 10,809 | 8,620 | 6,962 | 6,425 | 5,397 |
Company Profile
Company Details
| Full Name | Biogen Inc. |
| Country | United States |
| Employees | 7,400 |
| CEO | Michel Vounatsos |
Stock Information
| Ticker Symbol | BIIB |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers—General |
| Unique Identifier | NASDAQ: BIIB |
| IPO Date | September 16, 1991 |
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it is involved in developing Opicinumab, BIIB061, and BIIB091 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB110, and BIIB100 to treat neuromuscular disorders; BIIB054 and BIIB094 for treating movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and others; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB074 and BIIB095 for pain; and SB11 biosimilar, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration agreements with Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Eisai Company; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Acorda Therapeutics, Inc.; AbbVie Inc.; Skyhawk Therapeutics, Inc.; Neurimmune SubOne AG; Scribe Therapeutics Inc.; and Sangamo Therapeutics Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.